Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis Authors: Rupali Fuldeore, Adaeze Q. Amaefule, Gergana Georgieva, Tomomi Kimura, Baoguo Jiang, Kenneth H. Yu Published: 2026 ABSTRACT ABSTRACTAimTo assess healthcare resource utilization (HRU) and costs among patients with metastatic pancreatic cancer (mPC).Patients and methodsAdult US patients with an mPC diagnosis based on index date 1 January 2020–31 December 2022 were identified in the Merative MarketScan database. All-cause healthcare visits and costs (USD) were estimated per-person-per-month (PPPM) for 1 year post-index period. First-line (1L) treatments (≤90 days post-index) were categorized as FOLFIRINOX (leucovorin, fluorouracil, irinotecan, oxaliplatin)-based, gemcitabine+paclitaxel-based, other, or none.ResultsClaims from 2318 patients with mPC were included: 68.6% (1589/2318) with commercial and 31.4% (729/2318) with Medicare. Mean total costs PPPM were $34,215 with commercial and $15,158 with Medicare. A total of 25.7% (409/1589) of commercially insured patients and 43.2% (315/729) of Medicare-insured patients did not receive 1L treatment. Median (interquartile range) cumulative length of stay was 0.8 days (0.1–2.4) with commercial insurance and 0.7 days (0.0–2.4) with Medicare. All-cause PPPM costs were higher for patients without 1L treatment than with 1L treatment in both insurance types, primarily driven by inpatient and outpatient visits.ConclusionsPatients with mPC experienced high economic burden, mostly attributable to inpatient and outpatient costs. The high rate of patients with mPC not receiving 1L treatment merits further exploration. Introduction Pancreatic cancer (PC) is the third leading cause of cancer-related deaths in the US with nearly 52,000 estimated deaths in 2025 [1]. The American Cancer Society estimates over 67,000 new cases of PC will occur in the US in 2025, reflecting a 0.9% annual increase in new cases from 2013–2022 [1–3]. Additionally, the PC death rate has risen 0.2%–0.3% per year [1]. Early detection of PC is difficult, and approximately 50%–55% of patients have metastatic PC (mPC) at diagnosis [2], at which point prognosis is poor. The 5-year relative survival rate (2015–2021) was 13.3% for patients with PC and 3.2% for patients with mPC in the US [4]. Low survival rates are further impacted by limited treatment options, which have varying effectiveness. For patients with locally advanced or metastatic disease and favorable performance status (eg, Eastern Cooperative Oncology Group Performance Status [ECOG PS], 0–1), chemotherapy regimens commonly used in the US include 5-fluorouracil, leucovorin (folinic acid), irinotecan, and oxaliplatin (FOLFIRINOX) or modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine plus nanoparticle albumin-bound (nab)-paclitaxel (gem-pac) [5]. In 2024, 5-fluorouracil, leucovorin, irinotecan liposomal, and oxaliplatin (NALIRIFOX) was approved for first-line (1L) use in mPC [5,6]. Additionally, several immunotherapy and targeted treatments are approved in the US for specific types of pancreatic ductal adenocarcinoma (PDAC) (eg, microsatellite instability-high [MSI-H], deficient mismatch repair [dMMR], or high mutational burden [TMB-H]); however, these represent a small proportion of the total population of patients with PC [7]. Historically, considerable clinical and economic burden has been observed among patients with mPC [8–14]. However, these analyses have notably varied by sample size, insurance providers (ie, commercial or Medicare insurance), cancer stage, and consideration for type or presence of 1L treatment, and the therapy area would benefit from an update based on more recent sources. Better understanding of the associated burdens of mPC is necessary to identify how new therapies may fit into the existing treatment landscape, what factors most impact costs and healthcare resource utilization (HRU), and determine where gaps in care remain. This retrospective study utilized a US claims database to better understand the direct disease burden on all-cause HRU, costs, and to describe 1L treatment patterns in patients with mPC among commercially- and Medicare-insured populations. Patients & methods Data source The Merative MarketScan Claims Database is comprised of patient populations covered by commercial and Medicare insurance. The Medicare data includes Medicare Advantage and Medicare Supplement populations only. The database contains records for inpatients and outpatients covered under a variety of fee-for-service and managed care health plans, including exclusive provider organizations, preferred provider organizations, point of service plans, indemnity plans, and health maintenance organizations. The medical claims are linked to outpatient prescription drug claims and person-level enrollment data through the use of unique identifiers. The baseline period was defined as the 6-month period (180 days) before the date of first mPC diagnosis (ie, index date). The follow-up period was defined as the 12-month period (360 days) after the index date or until the last enrollment date with the coverage type at index, whichever occurred first. This study did not require Institutional Review Board review and was conducted in compliance with all applicable US requirements ensuring rights of patients in noninterventional studies. Study population Patients in the US aged 18 years or older with an index date during the identification period between 1 January 2020 and 31 December 2022 (Figure 1) were eligible. The diagnosis of mPC was defined as pancreatic cancer (ie, at least 2 visits > 30 days apart with any of the following International Classification of Diseases 10th revision [ICD-10] codes: C25.0, C25.1, C25.2, C25.3, C25.7, C25.8, C25.9) and metastatic disease (ie, at least 2 visits with ICD-10 codes for secondary malignancy in distant organs such as liver or bone [C77.0–C79.89]). Patients must have had continuous enrollment with medical coverage for at least 6 months before the first metastatic disease diagnosis. Exclusion criteria included ICD-10 code C25.4 (malignant neoplasm of endocrine pancreas) and at least 2 visits > 30 days apart with other primary cancer diagnosis during the baseline period (ICD-10 codes: C00.0–C24.9; C26.0–C43.9; C45.0–C76.8; C81.0–C97 [except for primary pancreatic cancer, primary non-melanoma skin cancer, or secondary malignancy]). Figure 1.Study design.The timeline illustrates the cohort entry date and first mPC diagnosis date, marked as Day 0, with an index date from 1 January 2020 to 31 December 2022. The eligibility assessment window spans Days −180 to 0, while the follow-up window covers Days 0 to 360. The x-axis represents time in days, ranging from −180 to 360.A timeline showing eligibility assessment and follow-up windows for this study of patients with mPC.Abbreviations: mPC, metastatic pancreatic cancer. Study design. Objectives and endpoints The analysis was a partial economic evaluation using a cost description approach, as classified by Drummond and colleagues [15]. The adopted viewpoint was that of the healthcare payer, consistent with the perspectives also described by Drummond et al. [15]. The primary objective was to estimate all-cause HRU and all-cause cost per-patient-per-month (PPPM) during the follow-up period. All-cause HRU was assessed based on number of inpatient visits, number of emergency department (ED) visits, number of outpatient visits, and cumulative length of stay (LoS; number of hospital days). All-cause costs were assessed based on cost for inpatient, outpatient (including laboratory tests and follow-up visits), ED visit costs, as well as pharmacy costs (outpatient dispensing costs for any drugs), anticancer medication costs (limited to those medications indicated for PC as of August 2024 in the US, including both outpatient dispensing and inpatient/outpatient administration costs), and hospice care costs. The secondary objective was to describe 1L regimens by the number and percentage of patients with 1L regimens that started ≤ 90 days from the index date, categorized as FOLFIRINOX, gem-pac, other (ie, any pancreatic adenocarcinoma systemic antineoplastic treatment regimen approved in the US as of August 2024 other than FOLFIRINOX or gem-pac) regimen, or no 1L regimen. Statistical analysis For HRU, the number of inpatient, ED, and outpatient visits were counted separately, and cumulative LoS was estimated as the number of days in hospital (discharge date – admission date +1). PPPM HRU and costs were calculated by dividing the total number of visits or total costs during the follow-up period by the total number of follow-up months for each patient; a month was defined as 30 days. The number of patients within each 1L regimen category was summarized by coverage types. All results are presented in a stratified manner: by coverage type (commercial and Medicare) and by 1L regimen (FOLFIRINOX-based, gem-pac, other, or no 1L). Study objectives were descriptive in nature, with no planned hypothesis testing. All variables are presented in terms of mean, standard deviation (SD), median, interquartile range (IQR), minimum and maximum for continuous variables, and by counts and percentages for categorical variables. As reported by Briggs and colleagues, as cost data fit a gamma distribution from 0 to positive infinity and can be highly skewed, both median and mean estimates are reported [16]. Results Baseline characteristics The analysis initially identified 2688 patients who met inclusion criteria. Of those, 106 patients with malignant neoplasm of endocrine pancreas and an additional 264 patients with other primary cancer diagnoses were excluded (Supplemental Table S1). In total, 2318 patients with mPC were included in the analysis: 68.6% (1589/2318) with commercial insurance and 31.4% (729/2318) with Medicare coverage (Table 1). Most patients in the commercial insurance population were aged between 55 and 64 years, whereas most patients in the Medicare population were aged between 65 and 74 years. Both groups had a slightly higher proportion of male patients than female patients. Approximately half of all the patients had liver metastases.Table 1.Baseline characteristics at index date. Coverage types TotalCommercialMedicarePatients, n23181589729Index year, n (%) 2020729 (31.4)530 (33.4)199 (27.3) 2021788 (34.0)526 (33.1)262 (35.9) 2022801 (34.6)533 (33.5)268 (36.8)Age at index, years Mean (SD)62.3 (10.69)56.6 (6.59)74.8 (6.42) Median61.058.074.0 Q1, Q356.0, 69.053.0, 62.070.0, 79.0 Min, max18, 9818, 6560, 98Age categories, n (%) 18–4493 (4.0)93 (5.9)0 45–54389 (16.8)389 (24.5)0 55–641105 (47.7)1095 (68.9)10 (1.4) 65–74383 (16.5)12 (0.8)371 (50.9) 75–84297 (12.8)0297 (40.7) 85+51 (2.2)051 (7.0)Sex, n (%) Male1261 (54.4)887 (55.8)374 (51.3) Female1057 (45.6)702 (44.2)355 (48.7)Geographic regions of the US, n (%) Northeast371 (16.0)250 (15.7)121 (16.6) North Central794 (34.3)384 (24.2)410 (56.2) South872 (37.6)713 (44.9)159 (21.8) West275 (11.9)238 (15.0)37 (5.1) Unknown6 (0.3)4 (0.3)2 (0.3)Site of metastases at indexa, n (%) Liver1262 (54.4)892 (56.1)370 (50.8) Lung232 (10.0)124 (7.8)108 (14.8) Peritoneum/retroperitoneum283 (12.2)197 (12.4)86 (11.8) Lymph nodes510 (22.0)363 (22.8)147 (20.2) Bone100 (4.3)66 (4.2)34 (4.7) Gastrointestinal tract231 (10.0)157 (9.9)74 (10.2) Other sites220 (9.5)141 (8.9)79 (10.8)Comorbiditiesb, n (%) Chronic pancreatitis91 (3.9)60 (3.8)31 (4.3) Diabetes mellitus837 (36.1)494 (31.1)343 (47.1) Obesity387 (16.7)254 (16.0)133 (18.2)aEach site was counted when multiple sites were recorded.bIndividual patients could have multiple comorbidities. Table 1.Baseline characteristics at index date. Coverage types TotalCommercialMedicarePatients, n23181589729Index year, n (%) 2020729 (31.4)530 (33.4)199 (27.3) 2021788 (34.0)526 (33.1)262 (35.9) 2022801 (34.6)533 (33.5)268 (36.8)Age at index, years Mean (SD)62.3 (10.69)56.6 (6.59)74.8 (6.42) Median61.058.074.0 Q1, Q356.0, 69.053.0, 62.070.0, 79.0 Min, max18, 9818, 6560, 98Age categories, n (%) 18–4493 (4.0)93 (5.9)0 45–54389 (16.8)389 (24.5)0 55–641105 (47.7)1095 (68.9)10 (1.4) 65–74383 (16.5)12 (0.8)371 (50.9) 75–84297 (12.8)0297 (40.7) 85+51 (2.2)051 (7.0)Sex, n (%) Male1261 (54.4)887 (55.8)374 (51.3) Female1057 (45.6)702 (44.2)355 (48.7)Geographic regions of the US, n (%) Northeast371 (16.0)250 (15.7)121 (16.6) North Central794 (34.3)384 (24.2)410 (56.2) South872 (37.6)713 (44.9)159 (21.8) West275 (11.9)238 (15.0)37 (5.1) Unknown6 (0.3)4 (0.3)2 (0.3)Site of metastases at indexa, n (%) Liver1262 (54.4)892 (56.1)370 (50.8) Lung232 (10.0)124 (7.8)108 (14.8) Peritoneum/retroperitoneum283 (12.2)197 (12.4)86 (11.8) Lymph nodes510 (22.0)363 (22.8)147 (20.2) Bone100 (4.3)66 (4.2)34 (4.7) Gastrointestinal tract231 (10.0)157 (9.9)74 (10.2) Other sites220 (9.5)141 (8.9)79 (10.8)Comorbiditiesb, n (%) Chronic pancreatitis91 (3.9)60 (3.8)31 (4.3) Diabetes mellitus837 (36.1)494 (31.1)343 (47.1) Obesity387 (16.7)254 (16.0)133 (18.2)aEach site was counted when multiple sites were recorded.bIndividual patients could have multiple comorbidities. Baseline characteristics at index date. aEach site was counted when multiple sites were recorded. bIndividual patients could have multiple comorbidities. Healthcare resource utilization For both coverage types, most patients (>70%) had at least one inpatient visit and nearly all (>99%) had at least one outpatient visit during the 1-year follow-up (Table 2; Figure 2). Approximately 44% of patients had at least one ED visit. Overall, the median (IQR) cumulative LoS was 0.8 days (0.1–2.4) for the commercially insured population and 0.7 days (0.0–2.4) for the Medicare-insured population. The mean (SD) was 2.0 days (3.2) for the commercially insured population and 2.0 days (3.4) for the Medicare-insured population. Patients without 1L treatment had a longer cumulative LoS than those with 1L treatment under both Medicare and commercial insurance. Figure 2.Healthcare resource utilization during the 1-year follow-up period.Two-part bar chart. A) Visits per patient per month, median (interquartile range). The horizontal axis categories are IP, OP, ED for Commercial insurance, then IP, OP, ED for Medicare. The vertical axis label is Visits PPPM, median (IQR), ranging from 0 to 8. Commercial insurance values: IP 0.2 (0.1–0.4); OP 6.0 (4.4–8.1); ED 0 (0.0–0.2). Medicare values: IP 0.2 (0.0–0.4); OP 5.7 (3.9–7.7); ED 0 (0.0–0.2). B) Length of stay. The horizontal axis label is Length of stay. The vertical axis label is Days, median (IQR), ranging from 0 to 3. Commercial insurance: 0.8 (0.1–2.4). Medicare: 0.7 (0.0–2.4). Legend labels: Commercial insurance; Medicare.A bar graph showing showing median inpatient, outpatient, and emergency department visits per-patient-per-month, and length of stay by insurance type.Abbreviations: ER, emergency department; IP, inpatient; IQR, interquartile range; OP, outpatient; PPPM; per-patient-per-month.Table 2.All-cause healthcare resource utilization per-patient-per-month during the 1-year follow-up period.Healthcare resourceCommercialMedicare1L Treatmenta1 L TreatmentaTotalN = 1589FOLFIRINOXbn = 675Gem-pacn = 256Othern = 249Nonen = 409TotalN = 729FOLFIRINOXbn = 126Gem-pacn = 165Othern = 123Nonen = 315InpatientPatients with ≥1 visit, n (%)1204 (75.8)512 (75.9)174 (68.0)199 (79.9)319 (78.0)523 (71.7)89 (70.6)111 (67.3)89 (72.4)234 (74.3)Number of visits Mean (SD)0.3 (0.3)0.2 (0.3)0.2 (0.3)0.3 (0.3)0.4 (0.4)0.3 (0.4)0.2 (0.3)0.2 (0.3)0.2 (0.3)0.4 (0.5) Median (IQR)0.2 (0.1–0.4)0.2 (0.1–0.3)0.2 (0.0–0.3)0.2 (0.1–0.4)0.3 (0.1–0.6)0.2 (0.0–0.4)0.1 (0.0–0.3)0.2 (0.0–0.3)0.2 (0.0–0.4)0.2 (0.0–0.6)OutpatientPatients with ≥1 visit, n (%)1586 (99.8)675 (100)256 (100)249 (100)406 (99.3)726 (99.6)126 (100)165 (100)123 (100)312 (99.0)Number of visits Mean (SD)6.6 (3.4)7.1 (3.0)6.5 (2.7)6.7 (3.5)5.8 (4.2)6.1 (3.2)7.0 (2.8)6.2 (2.6)6.6 (3.2)5.4 (3.5) Median (IQR)6.0 (4.4–8.1)6.7 (5.2–8.3)6.0 (4.6–8.0)5.9 (4.4–8.1)4.8 (3.0–7.3)5.7 (3.9–7.7)6.4 (5.1–8.3)5.8 (4.6–7.4)6.3 (4.6–8.1)4.6 (3.0–7.4)EDPatients with ≥1 visit, n (%)711 (44.7)320 (47.4)126 (49.2)102 (41.0)163 (39.9)327 (44.9)54 (42.9)68 (41.2)74 (60.2)131 (41.6)Number of visits Mean (SD)0.2 (0.3)0.1 (0.3)0.2 (0.3)0.1 (0.3)0.2 (0.4)0.2 (0.3)0.1 (0.3)0.1 (0.3)0.2 (0.3)0.2 (0.4) Median (IQR)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0.1 (0.0–0.2)0 (0.0–0.2)Cumulative LoS, days Mean (SD)2.0 (3.2)1.4 (1.9)1.5 (2.3)1.7 (2.5)3.5 (4.9)2.0 (3.4)1.1 (1.8)1.2 (1.9)1.5 (2.3)3.0 (4.4) Median (IQR)0.8 (0.1–2.4)0.7 (0.1–1.8)0.6 (0.0–1.9)0.9 (0.2–2.3)1.5 (0.2–5.1)0.7 (0.0–2.4)0.5 (0.0–1.2)0.4 (0.0–1.5)0.8 (0.0–1.7)1.2 (0.0–4.3)aThe first systemic anticancer therapy on or after the index date. Therapies that started before the index date and ended within 28 days from the index date were not counted. Therapies initiated within 90 days from the index date were counted. The follow-up period started on the index date (the first metastasis date), not from the initiation of 1L therapies.bIncluding fluorouracil, irinotecan, and oxaliplatin, with or without leucovorin (folinic acid). Levoleucovorin and leucovorin, as well as irinotecan and irinotecan liposomal, were counted interchangeably.Abbreviations: 1L, first-line; ED, emergency department; gem-pac, gemcitabine + paclitaxel-based; IQR, interquartile range; LoS, length of stay; SD, standard deviation. Healthcare resource utilization during the 1-year follow-up period. Table 2.All-cause healthcare resource utilization per-patient-per-month during the 1-year follow-up period.Healthcare resourceCommercialMedicare1L Treatmenta1 L TreatmentaTotalN = 1589FOLFIRINOXbn = 675Gem-pacn = 256Othern = 249Nonen = 409TotalN = 729FOLFIRINOXbn = 126Gem-pacn = 165Othern = 123Nonen = 315InpatientPatients with ≥1 visit, n (%)1204 (75.8)512 (75.9)174 (68.0)199 (79.9)319 (78.0)523 (71.7)89 (70.6)111 (67.3)89 (72.4)234 (74.3)Number of visits Mean (SD)0.3 (0.3)0.2 (0.3)0.2 (0.3)0.3 (0.3)0.4 (0.4)0.3 (0.4)0.2 (0.3)0.2 (0.3)0.2 (0.3)0.4 (0.5) Median (IQR)0.2 (0.1–0.4)0.2 (0.1–0.3)0.2 (0.0–0.3)0.2 (0.1–0.4)0.3 (0.1–0.6)0.2 (0.0–0.4)0.1 (0.0–0.3)0.2 (0.0–0.3)0.2 (0.0–0.4)0.2 (0.0–0.6)OutpatientPatients with ≥1 visit, n (%)1586 (99.8)675 (100)256 (100)249 (100)406 (99.3)726 (99.6)126 (100)165 (100)123 (100)312 (99.0)Number of visits Mean (SD)6.6 (3.4)7.1 (3.0)6.5 (2.7)6.7 (3.5)5.8 (4.2)6.1 (3.2)7.0 (2.8)6.2 (2.6)6.6 (3.2)5.4 (3.5) Median (IQR)6.0 (4.4–8.1)6.7 (5.2–8.3)6.0 (4.6–8.0)5.9 (4.4–8.1)4.8 (3.0–7.3)5.7 (3.9–7.7)6.4 (5.1–8.3)5.8 (4.6–7.4)6.3 (4.6–8.1)4.6 (3.0–7.4)EDPatients with ≥1 visit, n (%)711 (44.7)320 (47.4)126 (49.2)102 (41.0)163 (39.9)327 (44.9)54 (42.9)68 (41.2)74 (60.2)131 (41.6)Number of visits Mean (SD)0.2 (0.3)0.1 (0.3)0.2 (0.3)0.1 (0.3)0.2 (0.4)0.2 (0.3)0.1 (0.3)0.1 (0.3)0.2 (0.3)0.2 (0.4) Median (IQR)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0 (0.0–0.2)0.1 (0.0–0.2)0 (0.0–0.2)Cumulative LoS, days Mean (SD)2.0 (3.2)1.4 (1.9)1.5 (2.3)1.7 (2.5)3.5 (4.9)2.0 (3.4)1.1 (1.8)1.2 (1.9)1.5 (2.3)3.0 (4.4) Median (IQR)0.8 (0.1–2.4)0.7 (0.1–1.8)0.6 (0.0–1.9)0.9 (0.2–2.3)1.5 (0.2–5.1)0.7 (0.0–2.4)0.5 (0.0–1.2)0.4 (0.0–1.5)0.8 (0.0–1.7)1.2 (0.0–4.3)aThe first systemic anticancer therapy on or after the index date. Therapies that started before the index date and ended within 28 days from the index date were not counted. Therapies initiated within 90 days from the index date were counted. The follow-up period started on the index date (the first metastasis date), not from the initiation of 1L therapies.bIncluding fluorouracil, irinotecan, and oxaliplatin, with or without leucovorin (folinic acid). Levoleucovorin and leucovorin, as well as irinotecan and irinotecan liposomal, were counted interchangeably.Abbreviations: 1L, first-line; ED, emergency department; gem-pac, gemcitabine + paclitaxel-based; IQR, interquartile range; LoS, length of stay; SD, standard deviation. All-cause healthcare resource utilization per-patient-per-month during the 1-year follow-up period. aThe first systemic anticancer therapy on or after the index date. Therapies that started before the index date and ended within 28 days from the index date were not counted. Therapies initiated within 90 days from the index date were counted. The follow-up period started on the index date (the first metastasis date), not from the initiation of 1L therapies. bIncluding fluorouracil, irinotecan, and oxaliplatin, with or without leucovorin (folinic acid). Levoleucovorin and leucovorin, as well as irinotecan and irinotecan liposomal, were counted interchangeably. Abbreviations: 1L, first-line; ED, emergency department; gem-pac, gemcitabine + paclitaxel-based; IQR, interquartile range; LoS, length of stay; SD, standard deviation. Costs Median (IQR) total costs PPPM during the 1-year follow-up period were $26,417 (16,326–42,425) for commercially insured patients and $10,691 (6592–17,761) for Medicare-insured patients. Mean (SD) total all-cause costs were $34,215 (30,525) for commercially insured patients and $15,158 (20,637) for Medicare-insured patients. For both coverage types, total all-cause costs PPPM were primarily driven by inpatient and outpatient costs (Table 3, Figure 3). For commercially insured patients, monthly median (IQR) total all-cause costs were $25,983 (17,405– 42,035) for FOLFIRINOX; $27,834 (18,071–42,454) for gem-pac; $25,181 (15,202–39,192) for other 1L; and $27,493 (13,288–48,485) for no 1L treatment. Monthly mean (SD) total all-cause costs for patients with commercial insurance were $31,758 (20,925) for FOLFIRINOX; $33,459 (26,011) for gem-pac; $29,410 (20,034) for other 1L; and $41,667 (46,437) for no 1L treatment. Patients with Medicare insurance had monthly median (IQR) total costs of $11,031 (7605–15,958) for FOLFIRINOX; $11,070 (7874–17,446) for gem-pac; $10,041 (6730–16,529) for other 1L; and $9956 (4823–19,018) for no 1L treatment. For Medicare-insured patients, monthly mean (SD) total all-cause costs were $14,678 (13,577) for FOLFIRINOX; $14,084 (9056) for gem-pac; $13,482 (13,106) for other 1L; and $16,566 (28,296) for no 1L treatment. Median all-cause drug costs were $537 (128–1442) for commercially insured patients and $377 (103–812) for Medicare-insured patients. Mean (SD) all-cause drug costs were $1311 (3277) for commercially insured patients and $770 (1603) for Medicare-insured patients. There were no median costs ($0) for all-cause ED visits and hospice care for patients with either insurance type. Mean (SD) all-cause ED visits and for all-cause hospice care costs for commercially insured patients were $388 (1366) and $270 (741), respectively. For Medicare-insured patients, mean (SD) all-cause ED visits and for all-cause hospice care costs were $150 (359) and $50 (253), respectively. Figure 3.Mean all-cause costs (PPPM) during the 1-year follow-up period.A box plot showing mean all-cause costs, per-patient-per-month, United States dollars. The horizontal axis categories are Total, IP, OP, ED for Commercial insurance and Total, IP, OP, ED for Medicare. The vertical axis label is Mean all-cause costs, PPPM, USD, ranging from 0 to 50,000 in increments of 5000. Commercial insurance: Total box spans about 16,500 to 42,500, with a median line near 34,000 and a diamond marker near 26,500. IP box spans about 1000 to 19,500, with a median near 17,000 and a diamond near 9000. OP box spans about 7000 to 20,000, with a median near 15,500 and a diamond near 12,000. ED is plotted at 0. Medicare: Total box spans about 6500 to 17,500, with a median near 15,000 and a diamond near 10,500. IP box spans about 0 to 9500, with a median near 8000 and a diamond near 3500. OP box spans about 2500 to 8000, with a median near 6000 and a diamond near 4500. ED is plotted at 0. Legend entries: Commercial insurance; Medicare.A box plot showing mean all-cause costs per-patient-per-month by cost category and insurance type.Boxplots depict the mean (center line) with Q1 (lower) and Q3 values. Diamonds indicate median values.Abbreviations: ED, emergency department; IP, inpatient; OP, outpatient; PPPM, per-patient-per-month; Q, quartile; USD, US dollars.Table 3.All-cause costs per-patient-per-month during the 1-year follow-up period.Costs (PPPM), USDCommercialMedicare1 L Treatmenta1 L TreatmentaTotaln = 1589FOLFIRINOXbn = 675Gem-pacn = 256Othern = 249Nonen = 409Totaln = 729FOLFIRINOXbn = 126Gem-pacn = 165Othern = 123Nonen = 315Total Mean (SD)34,215 (30,525)31,758 (20,925)33,459 (26,011)29,410 (20,034)41,667 (46,437)15,158 (20,637)14,678 (13,577)14,084 (9056)13,482 (13,106)16,566 (28,296) Median (IQR)26,417 (16,326–42,425)25,983 (17,405–42,035)27,834 (18,071–42,454)25,181 (15,202–39,192)27,493 (13,288–48,485)10,691 (6592–17,761)11,031 (7605–15,958)11,070 (7874–17,446)10,041 (6730–16,529)9956 (4823–19,018)Inpatient Mean (SD)17,025 (28,827)12,566 (17,189)11,835 (20,214)13,610 (16,966)29,712 (45,801)8132 (19,677)5489 (9171)5144 (7282)6154 (10,055)11,528 (27,868) Median (IQR)7985 (635–19,671)6825 (798–16,603)5408 (0–15,100)8215 (2022–17,755)12,618 (2257–33,354)3230 (0–9419)2639 (0–7661)2402 (0–7058)2915 (0–8258)4532 (0–13,029)Outpatient Mean (SD)15,491 (13,559)17,450 (12,168)19,864 (16,079)13,888 (10,318)10,496 (14,134)6105 (5438)8283 (7542)8132 (4226)6123 (4605)4165 (4529) Median (IQR)12,122 (6906–20,171)14,087 (9323–21,774)16,013 (10,633–25,617)11,434 (6548–18,611)6474 (2683–12,575)4968 (2445–7831)6490 (3949–9664)7209 (5417–10, 133)4998 (3152–7580)2831 (1320–5410)ED Mean (SD)388 (1366)347 (906)555 (2588)314 (812)395 (1136)150 (359)144 (417)138 (295)160 (296)156 (388) Median (IQR)0 (0–285)0 (0–286)0 (0–421)0 (0–235)0 (0–247)0 (0–136)0 (0–112)0 (0–123)33 (0–193)0 (0–137)Pharmacyc Mean (SD)1311 (3277)1395 (4246)1204 (2018)1598 (2719)1063 (2200)770 (1603)762 (1091)671 (931)1046 (2528)718 (1585) Median (IQR)537 (128–1442)626 (202–1491)611 (159–1463)650 (137–2026)352 (66–1050)377 (103–812)337 (110–1120)430 (92–812)520 (213–1001)291 (71–696)Anticancer medicationd Mean (SD)2979 (5221)2728 (4401)8258 (7545)2367 (3999)–1282 (2303)739 (1382)3503 (2560)1825 (3022)– Median (IQR)595 (27–3798)888 (282–3262)6056 (3523– 10,654)623 (137–2655)–16 (0–1748)117 (0–808)2907 (1676–5009)396 (10–2882)–Hospice care Mean (SD)270 (741)184 (513)238 (604)230 (584)457 (1103)50 (253)49 (242)47 (234)26 (109)61 (302) Median (IQR)0 (0–155)0 (0–120)0 (0–136)0 (0–143)0 (0–268)00000aThe first systemic anticancer therapy on or after the index date. Therapies that started before the index date and ended within 28 days from the index date were not counted. Therapies initiated within 90 days from the index date were counted. The follow-up period started on the index date (the first metastasis date), not from the initiation of 1L therapies.bIncluding fluorouracil, irinotecan, and oxaliplatin, with or without leucovorin (folinic acid). Levoleucovorin and leucovorin, as well as irinotecan and irinotecan liposomal, were counted interchangeably.cIncluding outpatient dispensing costs for any medications.dIncluding costs for medications indicated for pancreatic cancer as of August 2024 in the US, including both outpatient dispensing and inpatient/outpatient administration costs.Abbreviations: 1L, first-line; ER, emergency department; gem-pac, gemcitabine + paclitaxel-based; IQR, interquartile range; LoS, length of stay; PPPM, per-patient-per-month; SD, standard deviation. Mean all-cause costs (PPPM) during the 1-year follow-up period. Table 3.All-cause costs per-patient-per-month during the 1-year follow-up period.Costs (PPPM), USDCommercialMedicare1 L Treatmenta1 L TreatmentaTotaln = 1589FOLFIRINOXbn = 675Gem-pacn = 256Othern = 249Nonen = 409Totaln = 729FOLFIRINOXbn = 126Gem-pacn = 165Othern = 123Nonen = 315Total Mean (SD)34,215 (30,525)31,758 (20,925)33,459 (26,011)29,410 (20,034)41,667 (46,437)15,158 (20,637)14,678 (13,577)14,084 (9056)13,482 (13,106)16,566 (28,296) Median (IQR)26,417 (16,326–42,425)25,983 (17,405–42,035)27,834 (18,071–42,454)25,181 (15,202–39,192)27,493 (13,288–48,485)10,691 (6592–17,761)11,031 (7605–15,958)11,070 (7874–17,446)10,041 (6730–16,529)9956 (4823–19,018)Inpatient Mean (SD)17,025 (28,827)12,566 (17,189)11,835 (20,214)13,610 (16,966)29,712 (45,801)8132 (19,677)5489 (9171)5144 (7282)6154 (10,055)11,528 (27,868) Median (IQR)7985 (635–19,671)6825 (798–16,603)5408 (0–15,100)8215 (2022–17,755)12,618 (2257–33,354)3230 (0–9419)2639 (0–7661)2402 (0–7058)2915 (0–8258)4532 (0–13,029)Outpatient Mean (SD)15,491 (13,559)17,450 (12,168)19,864 (16,079)13,888 (10,318)10,496 (14,134)6105 (5438)8283 (7542)8132 (4226)6123 (4605)4165 (4529) Median (IQR)12,122 (6906–20,171)14,087 (9323–21,774)16,013 (10,633–25,617)11,434 (6548–18,611)6474 (2683–12,575)4968 (2445–7831)6490 (3949–9664)7209 (5417–10, 133)4998 (3152–7580)2831 (1320–5410)ED Mean (SD)388 (1366)347 (906)555 (2588)314 (812)395 (1136)150 (359)144 (417)138 (295)160 (296)156 (388) Median (IQR)0 (0–285)0 (0–286)0 (0–421)0 (0–235)0 (0–247)0 (0–136)0 (0–112)0 (0–123)33 (0–193)0 (0–137)Pharmacyc Mean (SD)1311 (3277)1395 (4246)1204 (2018)1598 (2719)1063 (2200)770 (1603)762 (1091)671 (931)1046 (2528)718 (1585) Median (IQR)537 (128–1442)626 (202–1491)611 (159–1463)650 (137–2026)352 (66–1050)377 (103–812)337 (110–1120)430 (92–812)520 (213–1001)291 (71–696)Anticancer medicationd Mean (SD)2979 (5221)2728 (4401)8258 (7545)2367 (3999)–1282 (2303)739 (1382)3503 (2560)1825 (3022)– Median (IQR)595 (27–3798)888 (282–3262)6056 (3523– 10,654)623 (137–2655)–16 (0–1748)117 (0–808)2907 (1676–5009)396 (10–2882)–Hospice care Mean (SD)270 (741)184 (513)238 (604)230 (584)457 (1103)50 (253)49 (242)47 (234)26 (109)61 (302) Median (IQR)0 (0–155)0 (0–120)0 (0–136)0 (0–143)0 (0–268)00000aThe first systemic anticancer therapy on or after the index date. Therapies that started before the index date and ended within 28 days from the index date were not counted. Therapies initiated within 90 days from the index date were counted. The follow-up period started on the index date (the first metastasis date), not from the initiation of 1L therapies.bIncluding fluorouracil, irinotecan, and oxaliplatin, with or without leucovorin (folinic acid). Levoleucovorin and leucovorin, as well as irinotecan and irinotecan liposomal, were counted interchangeably.cIncluding outpatient dispensing costs for any medications.dIncluding costs for medications indicated for pancreatic cancer as of August 2024 in the US, including both outpatient dispensing and inpatient/outpatient administration costs.Abbreviations: 1L, first-line; ER, emergency department; gem-pac, gemcitabine + paclitaxel-based; IQR, interquartile range; LoS, length of stay; PPPM, per-patient-per-month; SD, standard deviation. All-cause costs per-patient-per-month during the 1-year follow-up period. aThe first systemic anticancer therapy on or after the index date. Therapies that started before the index date and ended within 28 days from the index date were not counted. Therapies initiated within 90 days from the index date were counted. The follow-up period started on the index date (the first metastasis date), not from the initiation of 1L therapies. bIncluding fluorouracil, irinotecan, and oxaliplatin, with or without leucovorin (folinic acid). Levoleucovorin and leucovorin, as well as irinotecan and irinotecan liposomal, were counted interchangeably. cIncluding outpatient dispensing costs for any medications. dIncluding costs for medications indicated for pancreatic cancer as of August 2024 in the US, including both outpatient dispensing and inpatient/outpatient administration costs. Abbreviations: 1L, first-line; ER, emergency department; gem-pac, gemcitabine + paclitaxel-based; IQR, interquartile range; LoS, length of stay; PPPM, per-patient-per-month; SD, standard deviation. 1L treatments FOLFIRINOX and gem-pac were the most frequent 1L treatments for patients with commercial insurance (42.5% [675/1589] and 16.1% [256/1589], respectively) and for patients with Medicare coverage (17.3% [126/729] and 22.6% [165/729], respectively) (Figure 4). Overall, 25.7% (409/1589) of patients with commercial insurance and 43.2% (315/729) with Medicare did not receive 1L treatment. Figure 4.First-line treatments for patients with mPC.a.The image showing two pie charts titled “Commercial insurance (n = 1589)” and “Medicare (n = 729)”. Commercial insurance (n = 1589) pie chart slices and labels: “FOLFIRINOX n = 675 42.5 percent”; “Gem-pac n = 256 16.1 percent”; “Other n = 249 15.7 percent”; “No 1L n = 409 25.7 percent”. Medicare (n = 729) pie chart slices and labels: “FOLFIRINOX n = 126 17.3 percent”; “Gem-pac n = 165 22.6 percent”; “Other n = 123 16.9 percent”; “No 1L n = 315 43.2 percent”.Pie chart of first-line treatments for patients with mPC by insurance type.aFOLFIRINOX included fluorouracil, irinotecan, and oxaliplatin, with or without leucovorin (folinic acid). Levoleucovorin and leucovorin, as well as irinotecan and irinotecan liposomal, were counted interchangeably. Gem-pac included gem-pac alone or plus other drug(s). Paclitaxel and nab-paclitaxel were counted interchangeably. “Other” included 1L treatments other than FOLFIRINOX-based or gem-pac regimens.Abbreviations: 1L, first-line; gem-pac, gemcitabine + paclitaxel-based; mPC, metastatic pancreatic cancer. First-line treatments for patients with mPC.a. Healthcare resource utilization by 1 L treatments For patients with commercial insurance, similar proportions of patients with and without 1L treatment regimens had at least 1 inpatient (68%–80%), outpatient (>99%), or ED visit (40%–49%) during the 1-year follow-up period. The mean number of provider visits PPPM was also similar between patients receiving and not receiving 1L treatment (0.2–0.3 vs 0.4 inpatient visits, 6.5–7.1 vs 5.8 outpatient visits, and 0.1–0.2 vs 0.2 ED visits, respectively). Mean cumulative LoS was lower with 1L therapy than without (1.4–1.7 vs 3.5 days, respectively; Table 2). With Medicare coverage, similar proportions of patients with inpatient (67%–74%) and outpatient visits (>99%) were observed across 1 L treatments. The proportion of patients with ED visits was 60% with other 1L treatment and 41%–43% with FOLFIRINOX, gem-pac, or no 1L treatment. The mean number of HRU visits PPPM was similar between patients with and without 1L treatment regimens (0.2 vs 0.4 inpatient visits, 6.2–7.0 vs 5.4 outpatient visits, and 0.1–0.2 vs 0.2 ED visits, respectively). Mean cumulative LoS was lower with 1L therapy vs without (1.1–1.5 vs 3.0 days, respectively; Table 2). Costs by 1L treatments Based on all-cause total costs by sites of service, outpatient costs were higher than inpatient and ED costs for patients receiving 1L treatment with both coverage types. Outpatient costs were also higher in patients with 1L treatment compared with outpatient costs in those who did not receive 1L treatment. For patients receiving no 1L treatments, inpatient costs were highest among all sites of service. (Table 3; Figure 5). Figure 5.All-cause per-patient-per-month costs by first-line treatments during the 1-year follow-up perioda.The image showing four grouped box plot charts titled FOLFIRINOX, Gem-Pac, Other and No 1L. Legend: Commercial insurance; Medicare. All charts share the vertical axis label Mean all-cause costs, PPPM, USD, ranging from 0 to 50,000 with ticks every 5000. All charts share the horizontal axis categories Total, IP, OP, ED for Commercial insurance, followed by Total, IP, OP, ED for Medicare. FOLFIRINOX: Commercial insurance boxes: Total about 17,000 to 42,000 with median about 32,000 and mean marker about 26,000; IP about 0 to 16,000 with median about 12,000 and mean about 7000; OP about 0 to 22,000 with median about 17,000 and mean about 14,000; ED near 0. Medicare boxes: Total about 8000 to 16,000 with median about 13,000 and mean about 11,000; IP about 0 to 8,000 with median about 6000 and mean about 3000; OP about 4000 to 10,000 with median about 7000 and mean about 6000; ED near 0. Gem-Pac: Commercial insurance Total about 18,000 to 43,000 with median about 33,000 and mean about 27,000; IP about 0 to 15,000 with median about 12,000 and mean about 6,000; OP about 11,000 to 26,000 with median about 20,000 and mean about 16,000; ED near 0. Medicare Total about 8000 to 18,000 with median about 14,000 and mean about 11,000; IP about 0 to 7000 with median about 5000 and mean about 2000; OP about 6000 to 10,000 with median about 8000 and mean about 8000; ED near 0. Other: Commercial insurance Total about 15,000 to 39,000 with median about 29,000 and mean about 25,000; IP about 2000 to 18,000 with median about 14,000 and mean about 8000; OP about 7000 to 19,000 with median about 14,000 and mean about 11,000; ED near 0. Medicare Total about 7000 to 16,000 with median about 12,000 and mean about 10,000; IP about 0 to 8000 with median about 6000 and mean about 3000; OP about 4000 to 8000 with median about 6000 and mean about 6000; ED near 0. No 1L: Commercial insurance Total about 13,000 to 49,000 with median about 41,000 and mean about 27,000; IP about 2000 to 33,000 with median about 30,000 and mean about 12,000; OP about 2000 to 13,000 with median about 9000 and mean about 6000; ED near 0. Medicare Total about 5000 to 19,000 with median about 17,000 and mean about 10,000; IP about 0 to 13,000 with median about 11,000 and mean about 4000; OP about 2000 to 6000 with median about 4000 and mean about 3000; ED near 0.A grouped box plot showing all-cause per-patient-per-month costs by first-line treatments and coverage.Boxplots depict the mean (center line) with Q1 (lower) and Q3 values. Diamonds indicate median values.aFOLFIRINOX included fluorouracil, irinotecan, and oxaliplatin, with or without leucovorin (folinic acid). Levoleucovorin and leucovorin, as well as irinotecan and irinotecan liposomal, were counted interchangeably. Gem-pac included gem-pac alone or plus other drug(s). Paclitaxel and nab-paclitaxel were counted interchangeably. “Other” included 1L treatments other than FOLFIRINOX-based or gem-pac regimens.Abbreviations: 1L, first-line; ED, emergency department; gem-pac, gemcitabine + paclitaxel-based; IP, inpatient; OP, outpatient; PPPM, per-patient-per-month; Q, quartile; USD, US dollars. All-cause per-patient-per-month costs by first-line treatments during the 1-year follow-up perioda. For patients with commercial insurance, mean all-cause costs PPPM were highest for patients without 1L treatment ($41,667), primarily driven by high inpatient costs ($29,712). Mean all-cause costs ranged from $29,410 to $33,459 PPPM with 1L treatment, primarily driven by outpatient costs ($13,888– 19,864) and inpatient costs ($11,835– 13,610). For patients with Medicare, mean all-cause costs PPPM were also highest for patients without 1L treatment ($16,566), primarily driven by inpatient costs ($11,528). Mean all-cause costs ranged from $13,482 to $14,678 PPPM with 1L treatment, primarily driven by outpatient costs ($6123–8283) and inpatient costs ($5144–6154). Discussion This retrospective cohort study using US claims database analysis assessed the HRU, costs, and 1L treatment patterns among patients with mPC from 2020 through 2022. High HRU and cost burden was observed in patients with mPC regardless of commercial insurance vs Medicare, mainly driven by outpatient visits in patients who received 1L treatment regimens and by inpatient visits in patients who did not receive any 1L treatment regimen. When treated, patients with mPC and commercial insurance were most frequently treated with the FOLFIRINOX-based regimen, while gem-pac was more common in the Medicare-insured population. Further investigation is needed to understand why a large portion of patients with mPC did not receive 1L treatment. Nearly all patients (>99%) in both populations had at least 1 outpatient visit during the 1-year follow-up period. The frequency of outpatient visits (6.6 outpatient visits PPPM with commercial insurance and 6.1 with Medicare) is unsurprising given the need for patients to visit healthcare providers for initial visits, follow-up appointments, treatments, and laboratory tests. Additionally, due to the high costs and limited availability of inpatient care, treatment is more commonly provided in outpatient settings when possible, resulting in more outpatient visits than inpatient and ED visits. These results are consistent with those of a retrospective claims-based analysis in patients with non-metastatic or metastatic PC (2001–2010), in which the rate of outpatient visits per person-year was higher than that of ED visits and inpatient stays [9]. In that study, DaCosta Byfield et al. found all-cause HRU and healthcare costs were not only significantly higher among patients with PC compared with patients without a cancer diagnosis, but were also significantly higher during the metastatic treatment phase than during the initial treatment phase [9]. Together our data provides further evidence that mPC is associated with a high HRU burden, driven largely by outpatient visits. Other studies support this high-cost burden for patients with mPC. In our study, mean all-cause costs were $34,215 for patients with commercial insurance and $15,158 for those with Medicare insurance. DaCosta Byfield et al. reported mean total all-cause healthcare costs were $15,480 PPPM among patients with PC, with a doubling of costs seen in the metastatic treatment phase versus the initial treatment phase of non-metastatic disease ($21,637 vs $10,358) [9]. In an earlier study of PC costs (2000–2007) in a population of Medicare-insured patients of advanced age (≥66 years), O’Neill et al. reported mean direct medical costs of $22,300 PPPM [12]. Both previous studies found high costs were primarily driven by inpatient costs. In our study, mean costs for patients with commercial insurance were $17,025 for inpatient and $15,491 for outpatient care; mean Medicare costs were $8132 for inpatient vs $6105 for outpatient care. Cost differences may reflect differences in study populations: DaCosta Byfield et al. included patient data from both commercial and Medicare Advantage populations, while O’Neill et al. focused their analysis on elderly patients on Medicare. Changes in medical care costs over the last decade may also contribute to these differences. In this study, the FOLFIRINOX-based regimen was the most common 1L regimen within the commercial population (42.5% [675/1589). In contrast, gem-pac was the most commonly used 1L regimen in the Medicare population (22.6% [165/729]). A similar pattern was seen in a retrospective claims analysis, in which patients with PC had higher use of FOLFIRINOX in the commercial population and greater use of gem-pac in the Medicare Advantage group [10]. Because the Medicare population consisted of an older population, this difference may be driven by ECOG PS and expected toxicity associated with FOLFIRINOX-based regimens [17]. In both coverage populations, a significant proportion of patients did not initiate 1 L therapy within 90 days from the first metastatic diagnosis (25.7% [409/1589] for commercial and 43.2% [315/729] for Medicare), consistent with previous findings in which 47%–57% of patients with mPC did not receive any systemic anticancer treatment [10,11]. In our study, these patients incurred the highest average all-cause and inpatient costs for both coverage populations compared with those receiving 1L therapy regimens. Among patients diagnosed with mPC between 2010 and 2017, previous analyses showed that higher mean all-cause costs PPPM were observed in untreated patients than those who received 1L therapy [11]. Doleh et al. similarly found patients receiving no 1L therapy after PC diagnosis between 2010 and 2017 had the largest proportion of costs attributable to inpatient care compared with patients receiving 1L systemic treatment regimens [10]. This may be due to the underlying disease burden of mPC, suggesting that patients who did not receive 1L treatment still required substantial healthcare resources, which may include intensive use of supportive care, repeated hospitalizations, systemic treatments, management of complications, palliative care, and outpatient care. Although the high rate of untreated individuals was not unexpected, it serves as an important call to better understand contributing factors. Hurdles to initiating treatment for patients with mPC are two-fold: not only do patients frequently present with comorbidities, compromised general health, and reduced functionality that make 1L chemotherapy not indicated or too risky, they also are faced with an unfavorable prognosis that could induce some clinicians and patients to choose not to start systemic anticancer treatments, preferring palliative therapies. Insurance coverage, health policies, treatment adherence, and patient preferences could also influence the choice not to receive treatment. A few studies have suggested factors such as advanced disease and older age may also play a role in the decision not to receive 1L treatment [10,18]. The findings of our study are notable given that an earlier observational study of patients with Medicare diagnosed with PC between 2000 and 2011—before the approval of FOLFIRINOX or gem-pac—reported the opposite trend: in patients with mPC, monthly total and cancer-attributable costs were higher for those receiving chemotherapy than those on best supportive care alone during both the initial and continuing phases [14]. Additional studies are needed to further explore contributing factors. Better clarity surrounding the clinical, economic, and supportive‑care burdens of mPC is needed to inform future therapeutic and policy decisions. By identifying the key drivers of HRU and cost burden and how these differ between commercially vs Medicare-insured patients with mPC, our study highlights where current treatment strategies may be insufficient. This evidence base is essential for determining how new systemic therapies and supportive‑care innovations may meaningfully reduce avoidable HRU, improve patient outcomes, and address persistent gaps in care. These findings may help support value‑based care efforts by helping clinicians, health systems, and payers anticipate unmet needs and allocate resources more effectively. Limitations The database included a greater portion of patients with commercial insurance than with Medicare (two-thirds vs one-third); therefore findings were reported separately rather than combined. Because this study only included patients from the MarketScan Research database who were commercially insured or had Medicare Advantage or Medicare Supplement coverage, the results may not be reflective of, or generalizable to, the entire US population with mPC. This data source is not linked to additional patient data including performance status, race, education, or socioeconomic data, nor does it include reasons for receiving a particular treatment or choosing not to be actively treated, which might have impacted visits and costs. The span of years covered by this analysis may have been affected by the “donut hole effect” of prescription drug coverage from Medicare; this was closed in 2025, and results may not be the same on or after 2025. Comparisons were based on numerical differences in descriptive statistics, not on inferential statistics. The study period included the years during the COVID-19 pandemic, and findings may have been impacted and may not be reflective of typical practices in the US. Additionally, this period was marked by severe inflation and significant changes to some individuals’ employment and health insurance [19,20], which may impact the generalizability of these findings. Conclusions A high burden of both HRU and costs in patients with mPC was demonstrated. Mean monthly inpatient costs were higher among patients who did not receive 1L treatment than those who did. Further investigation is needed to understand why many patients with mPC do not receive 1L treatment. This also highlights the unmet need for novel treatments that may potentially reduce the overall burden of mPC. Supplementary Material Supplemental Material